Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer

This study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to adults with extensive-stage small cell lung cancer (ES-SCLC), a fast-growing type of lung cancer that has spread widely in the body. To join the study, participants must meet the following conditions: * Be 18 years or older. * Have extensive-stage small cell lung cancer confirmed by lab tests. * Have not received chemotherapy or radiation for this type of lung cancer. * Be in good physical condition and have healthy organs based on medical tests. The study has

Trial Details

NCT ID
NCT07226999
Phase
PHASE2 / PHASE3
Sponsor
Pfizer
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • PF-08634404
  • Atezolizumab
  • Chemotherapy
Locations (sample)
  • Fayetteville, Arkansas, United States|36.06258,-94.15743
  • Coral Springs, Florida, United States|26.27119,-80.2706
  • Orange City, Florida, United States|28.94888,-81.29867
  • Tamarac, Florida, United States|26.21286,-80.24977
  • Cleveland, Ohio, United States|41.4995,-81.69541

Key Eligibility Criteria

  • Histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC).
  • Participants have not received systemic therapy (chemotherapy, radiotherapy, chemoradiation) for ES-SCLC.
  • Treatment-free for at least 6 months since last chemo/radiotherapy, among those treated (with curative intent) with prior chemo/radiotherapy for li…
  • Have at least one measurable lesion as the targeted lesion based on RECIST V1.1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →